Discharge with a wearable cardioverter defibrillator after coronary revascularization in patients with LVEF ≤35% was associated with lower 90-day mortality post-PCI (2% vs 10%, P<0.0001).
Cohort (n=4,958)
Yes
Absolute Event Rate: 2% vs 10%
p-value: p=<0.0001
BACKGROUND: Implantation of implantable cardioverter defibrillator for prevention of sudden cardiac death is deferred for 90 days after coronary revascularization, but mortality may be highest early after cardiac procedures in patients with ventricular dysfunction. We determined mortality risk in postrevascularization patients with left ventricular ejection fraction ≤35% and compared survival with those discharged with a wearable cardioverter defibrillator (WCD). METHODS AND RESULTS: Hospital survivors after surgical (coronary artery bypass graft surgery) or percutaneous (percutaneous coronary intervention PCI) revascularization with left ventricular ejection fraction ≤35% were included from Cleveland Clinic and national WCD registries. Kaplan-Meier, Cox proportional hazards, propensity score-matched survival, and hazard function analyses were performed. Early mortality hazard was higher among 4149 patients discharged without a defibrillator compared with 809 with WCDs (90-day mortality post-coronary artery bypass graft surgery 7% versus 3%, P=0.03; post-PCI 10% versus 2%, P<0.0001). WCD use was associated with adjusted lower risks of long-term mortality in the total cohort (39%, P<0.0001) and both post-coronary artery bypass graft surgery (38%, P=0.048) and post-PCI (57%, P<0.0001) cohorts (mean follow-up, 3.2 years). In propensity-matched analyses, WCD use remained associated with lower mortality (58% post-coronary artery bypass graft surgery, P=0.002; 67% post-PCI, P<0.0001). Mortality differences were not attributable solely to therapies for ventricular arrhythmia. Only 1.3% of the WCD group had a documented appropriate therapy. CONCLUSIONS: Patients with left ventricular ejection fraction ≤35% have higher early compared to late mortality after coronary revascularization, particularly after PCI. As early hazard seemed less marked in WCD users, prospective studies in this high-risk population are indicated to confirm whether WCD use as a bridge to left ventricular ejection fraction improvement or implantable cardioverter defibrillator implantation can improve outcomes after coronary revascularization.
Zishiri et al. (Sat,) conducted a cohort in Left ventricular dysfunction post-coronary revascularization (n=4,958). Wearable cardioverter defibrillator (WCD) vs. Discharge without a defibrillator was evaluated on 90-day mortality post-PCI (p=<0.0001). Discharge with a wearable cardioverter defibrillator after coronary revascularization in patients with LVEF ≤35% was associated with lower 90-day mortality post-PCI (2% vs 10%, P<0.0001).